Utah Med Prods Financials
This page shows Utah Med Prods (UTMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A shrinking but cash-rich franchise still mints cash because capital needs are tiny and operating margins stay high.
From FY2023 to FY2025, revenue fell23.3% while share count fell12.2% , so some of the business contraction was offset by repurchases rather than fully flowing into per-share results. That was possible because free cash flow stayed above net income and the business needed only$371K of capex in FY2025.
The balance sheet now looks overfunded for day-to-day operations: FY2025 ended with
The more important operating change is margin compression from lower scale, not a collapse in cash generation. Gross margin slipped from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Utah Med Prods's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Utah Med Prods has an operating margin of 29.6%, meaning the company retains $30 of operating profit per $100 of revenue. This strong profitability earns a score of 92/100, reflecting efficient cost management and pricing power. This is down from 33.2% the prior year.
Utah Med Prods's revenue declined 5.8% year-over-year, from $40.9M to $38.5M. This contraction results in a growth score of 13/100.
Utah Med Prods carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 37.62, Utah Med Prods holds $37.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Utah Med Prods converts 37.2% of revenue into free cash flow ($14.3M). This strong cash generation earns a score of 100/100.
Utah Med Prods's ROE of 9.5% shows moderate profitability relative to equity, earning a score of 35/100. This is down from 11.8% the prior year.
Utah Med Prods scores 40.95, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($206.9M) relative to total liabilities ($3.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Utah Med Prods passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Utah Med Prods generates $1.30 in operating cash flow ($14.7M OCF vs $11.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Utah Med Prods generated $38.5M in revenue in fiscal year 2025. This represents a decrease of 5.8% from the prior year.
Utah Med Prods's EBITDA was $14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.4% from the prior year.
Utah Med Prods reported $11.3M in net income in fiscal year 2025. This represents a decrease of 18.7% from the prior year.
Utah Med Prods earned $3.48 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 12.1% from the prior year.
Cash & Balance Sheet
Utah Med Prods generated $14.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.9% from the prior year.
Utah Med Prods held $85.8M in cash against $0 in long-term debt as of fiscal year 2025.
Utah Med Prods had 3M shares outstanding in fiscal year 2025. This represents a decrease of 4.5% from the prior year.
Margins & Returns
Utah Med Prods's gross margin was 57.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.
Utah Med Prods's operating margin was 29.6% in fiscal year 2025, reflecting core business profitability. This is down 3.6 percentage points from the prior year.
Utah Med Prods's net profit margin was 29.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.6 percentage points from the prior year.
Utah Med Prods's ROE was 9.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.3 percentage points from the prior year.
Capital Allocation
Utah Med Prods invested $668K in research and development in fiscal year 2025. This represents a decrease of 17.8% from the prior year.
Utah Med Prods spent $8.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 58.2% from the prior year.
Utah Med Prods invested $371K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 61.3% from the prior year.
UTMD Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.7M-3.6% | $9.0M-7.8% | $9.8M-1.4% | $10.0M+2.5% | $9.7M+6.0% | $9.2M-8.5% | $10.0M-3.8% | $10.4M |
| Cost of Revenue | $3.4M | N/A | $4.2M-3.4% | $4.4M+4.5% | $4.2M | N/A | $4.2M+1.4% | $4.1M |
| Gross Profit | $5.3M+0.3% | $5.3M-6.1% | $5.6M+0.2% | $5.6M+1.0% | $5.5M+4.0% | $5.3M-8.3% | $5.8M-7.2% | $6.3M |
| R&D Expenses | $154K | N/A | $167K+23.7% | $135K-12.3% | $154K | N/A | $172K-32.5% | $255K |
| SG&A Expenses | $2.6M | N/A | $2.8M+24.8% | $2.3M+1.5% | $2.2M | N/A | $2.3M-10.7% | $2.6M |
| Operating Income | $2.6M | N/A | $2.6M-18.3% | $3.2M+1.4% | $3.2M | N/A | $3.3M-2.8% | $3.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $578K | N/A | $678K-14.0% | $788K-3.5% | $817K | N/A | $616K-18.7% | $758K |
| Net Income | $2.6M+1.5% | $2.6M-2.5% | $2.6M-13.7% | $3.0M+0.2% | $3.0M+4.8% | $2.9M-18.6% | $3.6M+3.2% | $3.5M |
| EPS (Diluted) | $0.82+2.5% | $0.80-2.4% | $0.82-12.8% | $0.94+2.2% | $0.92+7.0% | $0.86-16.5% | $1.03+5.1% | $0.98 |
UTMD Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $124.4M+1.5% | $122.5M+0.5% | $122.0M+1.0% | $120.8M-1.4% | $122.5M0.0% | $122.5M-5.5% | $129.7M-0.3% | $130.0M |
| Current Assets | $100.4M+2.7% | $97.7M+1.3% | $96.5M+2.3% | $94.4M-2.1% | $96.4M+0.1% | $96.3M-5.2% | $101.7M-0.7% | $102.3M |
| Cash & Equivalents | $87.4M+1.9% | $85.8M+1.8% | $84.3M+2.5% | $82.2M-1.4% | $83.3M+0.4% | $83.0M-6.2% | $88.5M-0.9% | $89.2M |
| Inventory | $8.7M+9.9% | $7.9M-2.3% | $8.1M-1.4% | $8.2M-4.8% | $8.6M-1.9% | $8.8M-3.2% | $9.1M+0.5% | $9.1M |
| Accounts Receivable | $3.6M+3.2% | $3.5M-5.4% | $3.7M+2.6% | $3.6M-7.9% | $3.9M-3.7% | $4.1M+10.1% | $3.7M+1.4% | $3.7M |
| Goodwill | $13.9M-0.9% | $14.1M0.0% | $14.1M-1.0% | $14.2M+3.1% | $13.8M+1.4% | $13.6M-3.2% | $14.0M+2.8% | $13.6M |
| Total Liabilities | $4.0M+22.4% | $3.3M-12.1% | $3.7M+13.9% | $3.3M-40.3% | $5.5M+7.1% | $5.1M-7.0% | $5.5M-8.1% | $6.0M |
| Current Liabilities | $3.5M+34.9% | $2.6M-13.7% | $3.0M+33.6% | $2.3M-47.9% | $4.3M+15.1% | $3.8M+9.4% | $3.4M-12.8% | $3.9M |
| Long-Term Debt | $210K | $0 | N/A | N/A | $269K | $0 | N/A | N/A |
| Total Equity | $120.4M+0.9% | $119.3M+0.9% | $118.3M+0.6% | $117.5M+0.4% | $117.0M-0.3% | $117.4M-5.5% | $124.2M+0.1% | $124.1M |
| Retained Earnings | $130.3M+1.2% | $128.7M+0.5% | $128.0M+0.9% | $126.9M-1.0% | $128.2M-0.8% | $129.3M-3.5% | $134.1M-1.0% | $135.3M |
UTMD Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.1M-10.6% | $3.5M-10.3% | $3.9M+35.0% | $2.9M-35.6% | $4.5M+52.0% | $2.9M-23.8% | $3.9M+39.6% | $2.8M |
| Capital Expenditures | $130K+19.3% | $109K+303.7% | $27K-47.1% | $51K-72.3% | $184K+1944.4% | $9K-89.9% | $89K-19.1% | $110K |
| Free Cash Flow | $3.0M-11.5% | $3.4M-12.5% | $3.9M+36.5% | $2.8M-34.1% | $4.3M+46.2% | $2.9M-22.3% | $3.8M+42.0% | $2.7M |
| Investing Cash Flow | -$130K-19.3% | -$109K-303.7% | -$27K+47.1% | -$51K+72.3% | -$184K-1944.4% | -$9K+89.9% | -$89K+22.6% | -$115K |
| Financing Cash Flow | -$1.1M+43.3% | -$2.0M-20.1% | -$1.6M+63.4% | -$4.5M-5.9% | -$4.2M+45.3% | -$7.7M-57.5% | -$4.9M+31.6% | -$7.2M |
| Dividends Paid | $989K+1.2% | $977K-1.1% | $988K-1.3% | $1.0M-1.6% | $1.0M-2.0% | $1.0M-1.3% | $1.1M-2.7% | $1.1M |
| Share Buybacks | $128K-87.1% | $994K+52.2% | $653K-81.3% | $3.5M+8.3% | $3.2M-52.0% | $6.7M+73.5% | $3.9M-39.6% | $6.4M |
UTMD Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.6%+2.4pp | 58.2%+1.1pp | 57.1%+0.9pp | 56.2%-0.8pp | 57.0%-1.1pp | 58.1%+0.1pp | 58.0%-2.1pp | 60.1% |
| Operating Margin | 29.4% | N/A | 26.6%-5.5pp | 32.1%-0.4pp | 32.5% | N/A | 33.4%+0.4pp | 33.1% |
| Net Margin | 29.9%+1.5pp | 28.4%+1.6pp | 26.8%-3.8pp | 30.6%-0.7pp | 31.3%-0.4pp | 31.7%-3.9pp | 35.6%+2.4pp | 33.2% |
| Return on Equity | 2.2%+0.0pp | 2.1%-0.1pp | 2.2%-0.4pp | 2.6%0.0pp | 2.6%+0.1pp | 2.5%-0.4pp | 2.9%+0.1pp | 2.8% |
| Return on Assets | 2.1%0.0pp | 2.1%-0.1pp | 2.2%-0.4pp | 2.5%+0.0pp | 2.5%+0.1pp | 2.4%-0.4pp | 2.8%+0.1pp | 2.7% |
| Current Ratio | 28.64-9.0 | 37.62+5.6 | 32.06-9.8 | 41.87+19.6 | 22.29-3.3 | 25.64-4.0 | 29.59+3.6 | 25.98 |
| Debt-to-Equity | 0.000.0 | 0.00-0.0 | 0.030.0 | 0.03+0.0 | 0.000.0 | 0.00-0.0 | 0.040.0 | 0.05 |
| FCF Margin | 34.2%-3.1pp | 37.2%-2.0pp | 39.3%+10.9pp | 28.3%-15.7pp | 44.1%+12.1pp | 32.0%-5.7pp | 37.6%+12.2pp | 25.5% |
Similar Companies
Frequently Asked Questions
What is Utah Med Prods's annual revenue?
Utah Med Prods (UTMD) reported $38.5M in total revenue for fiscal year 2025. This represents a -5.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Utah Med Prods's revenue growing?
Utah Med Prods (UTMD) revenue declined by 5.8% year-over-year, from $40.9M to $38.5M in fiscal year 2025.
Is Utah Med Prods profitable?
Yes, Utah Med Prods (UTMD) reported a net income of $11.3M in fiscal year 2025, with a net profit margin of 29.3%.
What is Utah Med Prods's EBITDA?
Utah Med Prods (UTMD) had EBITDA of $14.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Utah Med Prods have?
As of fiscal year 2025, Utah Med Prods (UTMD) had $85.8M in cash and equivalents against $0 in long-term debt.
What is Utah Med Prods's gross margin?
Utah Med Prods (UTMD) had a gross margin of 57.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Utah Med Prods's operating margin?
Utah Med Prods (UTMD) had an operating margin of 29.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Utah Med Prods's net profit margin?
Utah Med Prods (UTMD) had a net profit margin of 29.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Utah Med Prods's return on equity (ROE)?
Utah Med Prods (UTMD) has a return on equity of 9.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Utah Med Prods's free cash flow?
Utah Med Prods (UTMD) generated $14.3M in free cash flow during fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Utah Med Prods's operating cash flow?
Utah Med Prods (UTMD) generated $14.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Utah Med Prods's total assets?
Utah Med Prods (UTMD) had $122.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Utah Med Prods's capital expenditures?
Utah Med Prods (UTMD) invested $371K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Utah Med Prods spend on research and development?
Utah Med Prods (UTMD) invested $668K in research and development during fiscal year 2025.
What is Utah Med Prods's current ratio?
Utah Med Prods (UTMD) had a current ratio of 37.62 as of fiscal year 2025, which is generally considered healthy.
What is Utah Med Prods's debt-to-equity ratio?
Utah Med Prods (UTMD) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Utah Med Prods's return on assets (ROA)?
Utah Med Prods (UTMD) had a return on assets of 9.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Utah Med Prods's Altman Z-Score?
Utah Med Prods (UTMD) has an Altman Z-Score of 40.95, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Utah Med Prods's Piotroski F-Score?
Utah Med Prods (UTMD) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Utah Med Prods's earnings high quality?
Utah Med Prods (UTMD) has an earnings quality ratio of 1.30x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Utah Med Prods?
Utah Med Prods (UTMD) scores 73 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.